Skip to main content
Advertisement

Main menu

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Special Sections
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET

User menu

  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Molecular Pharmacology
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET
  • My alerts
  • Log in
  • My Cart
Molecular Pharmacology

Advanced Search

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Special Sections
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Visit molpharm on Facebook
  • Follow molpharm on Twitter
  • Follow molpharm on LinkedIn
Research ArticleArticle

Structural Requirements of Transmembrane Domain 3 for Activation by the M1 Muscarinic Receptor Agonists AC-42, AC-260584, Clozapine, and N-Desmethylclozapine: Evidence for Three Distinct Modes of Receptor Activation

Tracy A. Spalding, Jian-Nong Ma, Thomas R. Ott, Mikael Friberg, Abhishek Bajpai, Stefania Risso Bradley, Robert E. Davis, Mark R. Brann and Ethan S. Burstein
Molecular Pharmacology December 2006, 70 (6) 1974-1983; DOI: https://doi.org/10.1124/mol.106.024901
Tracy A. Spalding
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jian-Nong Ma
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Thomas R. Ott
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Mikael Friberg
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Abhishek Bajpai
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Stefania Risso Bradley
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Robert E. Davis
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Mark R. Brann
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ethan S. Burstein
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF
Loading

Article Information

vol. 70 no. 6 1974-1983
DOI 
https://doi.org/10.1124/mol.106.024901
PubMed 
16959945

Published By 
American Society for Pharmacology and Experimental Therapeutics
Print ISSN 
0026-895X
Online ISSN 
1521-0111
History 
  • Received March 23, 2006
  • Accepted August 31, 2006
  • Published online November 16, 2006.

Article Versions

  • Earlier version (September 7, 2006 - 11:01).
  • Earlier version (September 14, 2006 - 07:19).
  • You are viewing the most recent version of this article.
Copyright & Usage 
The American Society for Pharmacology and Experimental Therapeutics

Author Information

  1. Tracy A. Spalding,
  2. Jian-Nong Ma,
  3. Thomas R. Ott,
  4. Mikael Friberg,
  5. Abhishek Bajpai,
  6. Stefania Risso Bradley,
  7. Robert E. Davis,
  8. Mark R. Brann and
  9. Ethan S. Burstein
  1. ACADIA Pharmaceuticals, Inc., San Diego, California
  1. Address correspondence to:
    Dr. Ethan S. Burstein, ACADIA Pharmaceuticals, Inc., 3911 Sorrento Valley Boulevard, San Diego, CA 92121. E-mail: eburstein{at}acadia-pharm.com
View Full Text

Statistics from Altmetric.com

Article usage

Article usage: September 2006 to July 2022

AbstractFullPdf
Sep 2006810115
Oct 2006150106
Nov 2006621690
Dec 2006252242
Jan 2007262526
Feb 2007172239
Mar 2007212127
Apr 2007162021
May 200791616
Jun 2007211820
Jul 2007111528
Aug 20077913
Sep 2007141924
Oct 200722920
Nov 2007161414
Dec 200731613
Jan 2008113723
Feb 2008132627
Mar 2008152627
Apr 2008132528
May 2008131321
Jun 200892923
Jul 2008202722
Aug 2008262717
Sep 2008292516
Oct 2008111519
Nov 2008151619
Dec 200861414
Jan 2009201714
Feb 200971213
Mar 200928219
Apr 200911919
May 2009111311
Jun 20096910
Jul 2009182712
Aug 200912106
Sep 20091058
Oct 20097510
Nov 20091535
Dec 20092436
Jan 2010121613
Feb 2010161216
Mar 20101558
Apr 201051612
May 2010141914
Jun 201071310
Jul 2010755
Aug 20101959
Sep 2010985
Oct 2010132114
Nov 2010589
Dec 2010779
Jan 2011121215
Feb 201110169
Mar 201111129
Apr 2011121110
May 2011999
Jun 2011111512
Jul 20111147
Aug 2011121312
Sep 20111387
Oct 2011121812
Nov 201117910
Dec 20111933
Jan 201212614
Feb 201281413
Mar 2012131210
Apr 20121586
May 20121086
Jun 201216312
Jul 201224511
Aug 20122375
Sep 2012121012
Oct 2012181011
Nov 2012191114
Dec 201217612
Jan 2013281718
Feb 2013939
Mar 20131956
Apr 2013222117
May 20131337
Jun 2013451
Jul 2013421
Aug 2013927
Sep 201313810
Oct 20131038
Nov 20131895
Dec 20131115
Jan 2014916
Feb 20141223
Mar 20141557
Apr 20141347
May 201426511
Jun 20145914
Jul 20141184
Aug 2014136
Sep 20148711
Oct 20141637
Nov 2014111916
Dec 20141387
Jan 20151411
Feb 20152525
Mar 201510512
Apr 2015846
May 20151869
Jun 20151166
Jul 2015191718
Aug 201517512
Sep 2015899
Oct 2015236
Nov 2015645
Dec 2015768
Jan 201622414
Feb 201617318
Mar 20168316
Apr 201614214
May 2016349
Jun 20161711
Jul 20167114
Aug 20165212
Sep 20161068
Oct 2016257
Nov 2016138
Dec 201611614
Jan 20170163
Feb 20173124
Mar 20172135
Apr 2017275
May 20170245
Jun 20172132
Jul 2017095
Aug 20175165
Sep 2017074
Oct 201722815
Nov 20173289
Dec 20171186
Jan 20181244
Feb 20181116
Mar 201862510
Apr 20182197
May 20180174
Jun 20180208
Jul 20182137
Aug 20181132
Sep 20180195
Oct 201812116
Nov 20181452
Dec 201824103
Jan 20192805
Feb 20193212
Mar 20191503
Apr 20191327
May 2019802
Jun 20198312
Jul 2019914
Aug 201916110
Sep 20191325
Oct 20191436
Nov 20191535
Dec 20192413
Jan 20201012
Feb 2020711
Mar 20201010
Apr 2020400
May 20201710
Jun 2020150
Jul 2020701
Aug 2020222
Sep 20201034
Oct 20201201
Nov 2020604
Dec 20201642
Jan 20217114
Feb 202112109
Mar 20212022
Apr 2021952
May 2021652
Jun 20211471
Jul 20211735
Aug 20211273
Sep 2021641
Oct 2021731
Nov 20212023
Dec 20211013
Jan 20222212
Feb 20221011
Mar 2022412
Apr 2022512
May 2022566
Jun 20221332
Jul 2022100

PreviousNext
Back to top

In this issue

Molecular Pharmacology: 70 (6)
Molecular Pharmacology
Vol. 70, Issue 6
1 Dec 2006
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover
  • Index by author
  • Back Matter (PDF)
  • Editorial Board (PDF)
  • Front Matter (PDF)
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Molecular Pharmacology article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Structural Requirements of Transmembrane Domain 3 for Activation by the M1 Muscarinic Receptor Agonists AC-42, AC-260584, Clozapine, and N-Desmethylclozapine: Evidence for Three Distinct Modes of Receptor Activation
(Your Name) has forwarded a page to you from Molecular Pharmacology
(Your Name) thought you would be interested in this article in Molecular Pharmacology.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Research ArticleArticle

Structural Requirements of Transmembrane Domain 3 for Activation by the M1 Muscarinic Receptor Agonists AC-42, AC-260584, Clozapine, and N-Desmethylclozapine: Evidence for Three Distinct Modes of Receptor Activation

Tracy A. Spalding, Jian-Nong Ma, Thomas R. Ott, Mikael Friberg, Abhishek Bajpai, Stefania Risso Bradley, Robert E. Davis, Mark R. Brann and Ethan S. Burstein
Molecular Pharmacology December 1, 2006, 70 (6) 1974-1983; DOI: https://doi.org/10.1124/mol.106.024901

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

Share
Research ArticleArticle

Structural Requirements of Transmembrane Domain 3 for Activation by the M1 Muscarinic Receptor Agonists AC-42, AC-260584, Clozapine, and N-Desmethylclozapine: Evidence for Three Distinct Modes of Receptor Activation

Tracy A. Spalding, Jian-Nong Ma, Thomas R. Ott, Mikael Friberg, Abhishek Bajpai, Stefania Risso Bradley, Robert E. Davis, Mark R. Brann and Ethan S. Burstein
Molecular Pharmacology December 1, 2006, 70 (6) 1974-1983; DOI: https://doi.org/10.1124/mol.106.024901
del.icio.us logo Digg logo Reddit logo Twitter logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Materials and Methods
    • Results
    • Discussion
    • Acknowledgments
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF

Related Articles

Cited By...

More in this TOC Section

  • Human mAb 3F1 targeting the fuctional epitopes of Siglec-15
  • The regulation and mechanisms of ImKTX58 on KV1.3 channel
  • EIPA, HMA and SMN2 gene regulation
Show more Articles

Similar Articles

Advertisement
  • Home
  • Alerts
Facebook   Twitter   LinkedIn   RSS

Navigate

  • Current Issue
  • Fast Forward by date
  • Fast Forward by section
  • Latest Articles
  • Archive
  • Search for Articles
  • Feedback
  • ASPET

More Information

  • About Molecular Pharmacology
  • Editorial Board
  • Instructions to Authors
  • Submit a Manuscript
  • Customized Alerts
  • RSS Feeds
  • Subscriptions
  • Permissions
  • Terms & Conditions of Use

ASPET's Other Journals

  • Drug Metabolism and Disposition
  • Journal of Pharmacology and Experimental Therapeutics
  • Pharmacological Reviews
  • Pharmacology Research & Perspectives
ISSN 1521-0111 (Online)

Copyright © 2022 by the American Society for Pharmacology and Experimental Therapeutics